News

  1. Jan
  2. Feb
  3. Mar
  4. Apr
  5. May
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct
  11. Nov
  12. Dec

July

Jul.13, 2020 Release
Shionogi Announces Corporate Reorganization and Personnel Reassignment
Jul.13, 2020 Release
Notice Regarding the Signing of the Agreements on the Establishment of the Joint Ventures with Ping An Insurance, the Establishment of a New Subsidiary, the Signing of the Agreements on Transfer of Subsidiary Shares and Equity Stakes, and the Disposal of Treasury Shares by Way of Third-Party Allotment
Jul.10, 2020 Release
New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion
- Partnership aims to bring 2 to 4 new antibiotics to patients by the end of the decade and facilitate needed long-term policy solutions -
Jul.09, 2020 Release
Shionogi Included in Stock Indices (Index) for ESG Investing: FTSE4Good Index Series and FTSE Blossom Japan Index
- Shionogi Has Become the Constituent of the All Four Indices Used by Japan's Government Pension Investment Fund (GPIF) -
Jul.09, 2020 Release
BLOCKSTONE Study of Xofluza® (Baloxavir Marboxil) for the Prevention of Influenza in Household Contacts Published in The New England Journal of Medicine

June

Jun.30, 2020 Release
Signing of a new contract with StemRIM
- Toward Investigator-initiated Clinical Study Implementation of S-005151 [Generic Name: Redasemtide] -
Jun.23, 2020 Release
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Jun.22, 2020 Release
Business Partnership with Nihon University, Gunma University, and Tokyo Medical University for a Rapid Diagnostic Methods for Viruses in the Field of Infectious Diseases, Including Novel Coronavirus
- A Rapid Diagnostic Method with High Sensitivity that can be Visually Determined without the Need for a Detection Device in 25 Minutes of Reaction from Samples such as Saliva -
Jun.19, 2020 Release
Shionogi Announces Commitment to Fight COVID-19 (3)
Jun.09, 2020 Release
CAPSTONE-2 study of Xofluza® (Baloxavir Marboxil) for the Treatment of Influenza Published in The Lancet Infectious Diseases
Jun.03, 2020 Release
Shionogi Announces Commitment to Fight COVID-19 (2)
Jun.03, 2020 Release
IgG/IgM Antibody-test Kit for COVID-19 launched in Japan
Jun.02, 2020 Release
FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Jun.01, 2020 Release
Notice Regarding a New Medium-Term Business Plan
May.29, 2020 Notice
Presentation Material for 2030 vision and Medium-Term Business Plan "Shionogi Transformation Strategy (STS2030)"

May

May.26, 2020 Release
Notice Regarding Tetra becoming a wholly owned subsidiary of Shionogi
May.25, 2020 Notice
“Notice of Convocation of the 155th Annual General Meeting of Shareholders” and “Items Disclosed on Internet Concerning Notice of Convocation of the 155th Annual General Meeting of Shareholders”Open in a new tab
May.12, 2020 Notice
Presentation Material for FY2019 Financial Results
May.11, 2020 Notice
Financial Results for FY2019

April

Apr.28, 2020 Release
SHIONOGI RECEIVES EUROPEAN COMMISSION MARKETING AUTHORISATION FOR FETCROJA® (CEFIDEROCOL) FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE BACTERIA IN ADULTS WITH LIMITED TREATMENT OPTIONS
Apr.27, 2020 Release
Notice Regarding a Development Decision of Vaccine for COVID-19
Apr.24, 2020 Release
Notice of Revisions to Dividend Forecasts (Divident Increase)
Apr.22, 2020 Release
Position and Policy Regarding Reduction of the Investment Unit
Apr.14, 2020 Release
Shionogi Announces Commitment to Fight COVID-19
Apr.07, 2020 Release
Shionogi Issues the Shionogi Group Smoke-Free Declaration with the Aim of Achieving a Zero Smoking Rate among Its Employees
Apr.07, 2020 Release
Notice Regarding Completion of Cancellation of Treasury Shares(Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act)
Apr.01, 2020 Release
A New Maternal and Child Healthcare Program Kicks Off in Kilifi County, Kenya The Mother to Mother SHIONOGI Project Enters Its Second Phase with the Aim of Improving Health Access

March

Mar.31, 2020 Release
Shionogi Filed for the Supplemental New Drug Application of Xofluza® in Taiwan for the Post-Exposure Prophylaxis of Influenza Virus Infection
Mar.31, 2020 Release
Shionogi Joins The Valuable 500, an International Initiative for Promoting Disability Inclusion
Mar.31, 2020 Notice
Press Conference
Mar.30, 2020 Release
Notice Regarding the Signing of the Basic Agreement with Ping An Insurance for a Capital and Business Alliance including the Disposal of Treasury Shares by Way of Third-Party Allotment
Mar.30, 2020 Release
Notice Regarding Changes of Cancellation of Treasury Shares（Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act）
Mar.27, 2020 Release
FDA Accepts a New Drug Application for a New Formulation and Two Supplemental New Drug Applications for XOFLUZA® (Baloxavir Marboxil)
Mar.26, 2020 Notice
Transcript of the R&D Meeting
Mar.19, 2020 Notice
R&D Meeting
Mar.17, 2020 Release
Business Partnership with Micro Blood Science Inc. for an IgG/IgM Antibody-test Kit for COVID-19
Mar.10, 2020 Release
Partnership Agreement between Yabu City, Hyogo, and Shionogi on the Improvement of Community Healthcare
Mar.09, 2020 Release
Notice Regarding the Status and Completion of Acquisition of Own Shares(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
Mar.06, 2020 Release
Shionogi Certified as Health and Productivity Management Organization 2020 for Fourth Consecutive Year
Mar.06, 2020 Release
Shionogi and Tetra Therapeutics Entered into New Strategic Collaboration for BPN14770, the Drug Candidates for the Treatment of Brain Disorders Marked by Cognitive and Memory Deficits
Mar.03, 2020 Release
Shionogi Receives Grand Prize Company Award for Corporate Governance of the Year 2019
Mar.03, 2020 Release
SHIONOGI RECEIVES POSITIVE CHMP OPINION FOR FETCROJA® (CEFIDEROCOL) FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE BACTERIA IN ADULT PATIENTS WITH LIMITED TREATMENT OPTIONS

February

Feb.25, 2020 Release
SHIONOGI to Announce Executive Appointments, Corporate Reorganization and Personnel Reassignment
Feb.25, 2020 Release
Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S.
Feb.07, 2020 Release
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
Feb.04, 2020 Release
Shionogi Gains High Rating in Survey by CDP- Rated A- for “Climate Change” and Chosen as an A-List Company for “Water security” -
Feb.03, 2020 Notice
Financial Results for the Third Quarter of FY2019

January

Jan.08, 2020 Release
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Back number

This website uses cookies for analytics and functionality purposes. To change your cookie settings or find out more, click here.

If you continue browsing our website, you accept these cookies.